BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) Fundamental Analysis & Valuation

BIT:1BMRN • US09061G1013

Current stock price

48.12 EUR
-2.58 (-5.09%)
Last:

This 1BMRN.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. 1BMRN.MI Profitability Analysis

1.1 Basic Checks

  • In the past year 1BMRN was profitable.
  • 1BMRN had a positive operating cash flow in the past year.
  • Of the past 5 years 1BMRN 4 years were profitable.
  • Each year in the past 5 years 1BMRN had a positive operating cash flow.
1BMRN.MI Yearly Net Income VS EBIT VS OCF VS FCF1BMRN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

1.2 Ratios

  • 1BMRN's Return On Assets of 6.83% is amongst the best of the industry. 1BMRN outperforms 82.35% of its industry peers.
  • With a decent Return On Equity value of 8.59%, 1BMRN is doing good in the industry, outperforming 80.00% of the companies in the same industry.
  • The Return On Invested Capital of 1BMRN (7.69%) is better than 84.71% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for 1BMRN is significantly below the industry average of 11.35%.
  • The 3 year average ROIC (3.73%) for 1BMRN is below the current ROIC(7.69%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.83%
ROE 8.59%
ROIC 7.69%
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1BMRN.MI Yearly ROA, ROE, ROIC1BMRN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

1.3 Margins

  • Looking at the Profit Margin, with a value of 16.82%, 1BMRN belongs to the top of the industry, outperforming 82.35% of the companies in the same industry.
  • The Operating Margin of 1BMRN (20.21%) is better than 83.53% of its industry peers.
  • 1BMRN's Gross Margin of 81.32% is fine compared to the rest of the industry. 1BMRN outperforms 70.59% of its industry peers.
  • In the last couple of years the Gross Margin of 1BMRN has remained more or less at the same level.
Industry RankSector Rank
OM 20.21%
PM (TTM) 16.82%
GM 81.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
1BMRN.MI Yearly Profit, Operating, Gross Margins1BMRN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. 1BMRN.MI Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so 1BMRN is destroying value.
  • Compared to 1 year ago, 1BMRN has more shares outstanding
  • The number of shares outstanding for 1BMRN has been increased compared to 5 years ago.
  • The debt/assets ratio for 1BMRN has been reduced compared to a year ago.
1BMRN.MI Yearly Shares Outstanding1BMRN.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
1BMRN.MI Yearly Total Debt VS Total Assets1BMRN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 5.44 indicates that 1BMRN is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of 1BMRN (5.44) is better than 78.82% of its industry peers.
  • The Debt to FCF ratio of 1BMRN is 0.72, which is an excellent value as it means it would take 1BMRN, only 0.72 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.72, 1BMRN belongs to the top of the industry, outperforming 85.88% of the companies in the same industry.
  • A Debt/Equity ratio of 0.10 indicates that 1BMRN is not too dependend on debt financing.
  • 1BMRN has a Debt to Equity ratio of 0.10. This is in the better half of the industry: 1BMRN outperforms 63.53% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.72
Altman-Z 5.44
ROIC/WACC0.92
WACC8.4%
1BMRN.MI Yearly LT Debt VS Equity VS FCF1BMRN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

  • A Current Ratio of 4.83 indicates that 1BMRN has no problem at all paying its short term obligations.
  • 1BMRN has a better Current ratio (4.83) than 78.82% of its industry peers.
  • 1BMRN has a Quick Ratio of 3.10. This indicates that 1BMRN is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of 1BMRN (3.10) is better than 68.24% of its industry peers.
Industry RankSector Rank
Current Ratio 4.83
Quick Ratio 3.1
1BMRN.MI Yearly Current Assets VS Current Liabilites1BMRN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. 1BMRN.MI Growth Analysis

3.1 Past

  • 1BMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.00%, which is quite impressive.
  • 1BMRN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.39%.
  • The Revenue has been growing by 10.86% on average over the past years. This is quite good.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%

3.2 Future

  • Based on estimates for the next years, 1BMRN will show a very strong growth in Earnings Per Share. The EPS will grow by 28.19% on average per year.
  • The Revenue is expected to grow by 7.22% on average over the next years.
EPS Next Y28.21%
EPS Next 2Y44.96%
EPS Next 3Y35.45%
EPS Next 5Y28.19%
Revenue Next Year12.62%
Revenue Next 2Y11.16%
Revenue Next 3Y10.75%
Revenue Next 5Y7.22%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
1BMRN.MI Yearly Revenue VS Estimates1BMRN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B
1BMRN.MI Yearly EPS VS Estimates1BMRN.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

8

4. 1BMRN.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 21.58, which indicates a rather expensive current valuation of 1BMRN.
  • Compared to the rest of the industry, the Price/Earnings ratio of 1BMRN indicates a rather cheap valuation: 1BMRN is cheaper than 84.71% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.78. 1BMRN is around the same levels.
  • Based on the Price/Forward Earnings ratio of 12.35, the valuation of 1BMRN can be described as correct.
  • Based on the Price/Forward Earnings ratio, 1BMRN is valued cheaply inside the industry as 95.29% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of 1BMRN to the average of the S&P500 Index (23.54), we can say 1BMRN is valued slightly cheaper.
Industry RankSector Rank
PE 21.58
Fwd PE 12.35
1BMRN.MI Price Earnings VS Forward Price Earnings1BMRN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 1BMRN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 1BMRN is cheaper than 83.53% of the companies in the same industry.
  • 94.12% of the companies in the same industry are more expensive than 1BMRN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 13.34
EV/EBITDA 14
1BMRN.MI Per share data1BMRN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

  • 1BMRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of 1BMRN may justify a higher PE ratio.
  • 1BMRN's earnings are expected to grow with 35.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.76
PEG (5Y)N/A
EPS Next 2Y44.96%
EPS Next 3Y35.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 1BMRN.MI Dividend Analysis

5.1 Amount

  • 1BMRN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

1BMRN.MI Fundamentals: All Metrics, Ratios and Statistics

BIOMARIN PHARMACEUTICAL INC

BIT:1BMRN (1/23/2026, 7:00:00 PM)

48.12

-2.58 (-5.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-27
Earnings (Next)02-25
Inst Owners97.82%
Inst Owner ChangeN/A
Ins Owners0.64%
Ins Owner ChangeN/A
Market Cap9.24B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts81.88
Price Target80.11 (66.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)-2.74%
PT rev (3m)-2.74%
EPS NQ rev (1m)-29.03%
EPS NQ rev (3m)-24.43%
EPS NY rev (1m)-5.52%
EPS NY rev (3m)-16.53%
Revenue NQ rev (1m)0.68%
Revenue NQ rev (3m)0.77%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)0.12%
Valuation
Industry RankSector Rank
PE 21.58
Fwd PE 12.35
P/S 3.56
P/FCF 13.34
P/OCF 12.06
P/B 1.82
P/tB 1.96
EV/EBITDA 14
EPS(TTM)2.23
EY4.63%
EPS(NY)3.9
Fwd EY8.1%
FCF(TTM)3.61
FCFY7.49%
OCF(TTM)3.99
OCFY8.3%
SpS13.51
BVpS26.45
TBVpS24.58
PEG (NY)0.76
PEG (5Y)N/A
Graham Number36.43
Profitability
Industry RankSector Rank
ROA 6.83%
ROE 8.59%
ROCE 9.17%
ROIC 7.69%
ROICexc 9.82%
ROICexgc 10.68%
OM 20.21%
PM (TTM) 16.82%
GM 81.32%
FCFM 26.69%
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.72
Debt/EBITDA 0.84
Cap/Depr 106.6%
Cap/Sales 2.85%
Interest Coverage 85.91
Cash Conversion 129.08%
Profit Quality 158.68%
Current Ratio 4.83
Quick Ratio 3.1
Altman-Z 5.44
F-Score8
WACC8.4%
ROIC/WACC0.92
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y28.21%
EPS Next 2Y44.96%
EPS Next 3Y35.45%
EPS Next 5Y28.19%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.62%
Revenue Next 2Y11.16%
Revenue Next 3Y10.75%
Revenue Next 5Y7.22%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.1%
EBIT Next 3Y41.17%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%

BIOMARIN PHARMACEUTICAL INC / 1BMRN.MI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?

ChartMill assigns a fundamental rating of 6 / 10 to 1BMRN.MI.


What is the valuation status for 1BMRN stock?

ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (1BMRN.MI). This can be considered as Undervalued.


How profitable is BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) stock?

BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) has a profitability rating of 7 / 10.


What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) stock?

The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) is expected to grow by 28.21% in the next year.